רווח לפני תשלום ריבית, מסים ופחת: bauschhealth.com (BHC)

Massive debts limit the development and maneuverability of Bausch Health Companies (BHC). Growth is driven by Xifaxan sales and a potential exit from Bausch + Lomb assets. Demand for prescriptions remains stable, but pricing power is constrained by loans. The company's consolidated EBITDA demonstrates current efficiency in an environment of expensive capital, where the latest value is recorded as 4206.50.

This indicator is critical when stress-testing assets to assess a business's ability to service its obligations. The metric measures daily cash flow from core operations before depreciation and taxes; therefore, analyzing operating income before taxes and depreciation allows for the identification of risks regarding the profit degradation of Bausch Health Companies (BHC) amid high debt levels and regulatory pressure in the US.